Slow Capital Inc. Has $2.40 Million Stake in Danaher Corporation (NYSE:DHR)

Slow Capital Inc. cut its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 16.6% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,700 shares of the conglomerate's stock after selling 2,327 shares during the period. Slow Capital Inc.'s holdings in Danaher were worth $2,400,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Norges Bank acquired a new stake in shares of Danaher in the fourth quarter worth $2,130,740,000. GAMMA Investing LLC lifted its stake in shares of Danaher by 24,958.2% in the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock worth $383,524,000 after buying an additional 1,863,381 shares during the last quarter. Two Sigma Advisers LP lifted its stake in shares of Danaher by 4,248.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after buying an additional 1,601,800 shares during the last quarter. Capital World Investors lifted its stake in shares of Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock worth $1,460,215,000 after buying an additional 1,566,658 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in shares of Danaher by 460.6% in the fourth quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock worth $309,558,000 after buying an additional 1,107,998 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the sale, the chairman owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. This trade represents a 28.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president directly owned 15,179 shares of the company's stock, valued at $3,005,442. This represents a 51.01% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by company insiders.

Danaher Trading Up 0.2%

Shares of NYSE:DHR traded up $0.42 during mid-day trading on Thursday, reaching $193.72. The stock had a trading volume of 1,280,317 shares, compared to its average volume of 3,511,560. The firm has a 50 day simple moving average of $196.12 and a two-hundred day simple moving average of $205.72. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $281.70. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The firm has a market cap of $138.64 billion, a PE ratio of 37.58, a price-to-earnings-growth ratio of 2.71 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The business had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. On average, research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.66%. Danaher's dividend payout ratio is presently 24.85%.

Wall Street Analyst Weigh In

DHR has been the subject of several research analyst reports. Leerink Partners upped their target price on shares of Danaher from $225.00 to $230.00 and gave the company an "outperform" rating in a research note on Wednesday, April 23rd. Jefferies Financial Group lowered their price target on shares of Danaher from $260.00 to $230.00 and set a "buy" rating on the stock in a report on Tuesday, April 22nd. Guggenheim reissued a "buy" rating and issued a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. Evercore ISI lowered their price target on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Finally, Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $248.43.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.